Search Result
Results for "
astrocytes
" in MedChemExpress (MCE) Product Catalog:
5
Biochemical Assay Reagents
4
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P1410
-
GsMTx4
Maximum Cited Publications
112 Publications Verification
|
TRP Channel
Piezo Channel
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
GsMTx4 is a spider venom peptide that selectively inhibits cationic-permeable mechanosensitive channels (MSCs) belonging to the Piezo and TRP channel families. GsMTx4 also blocks cation-selective stretch-activated channels (SACs) , attenuates lysophosphatidylcholine (LPC)-induced astrocyte toxicity and microglial reactivity. GsMTx4 is an important pharmacological tool for identifying the role of these excitatory MSCs in normal physiology and pathology .
|
-
-
- HY-100803
-
|
2-Aminoethanesulfinic acid
|
Endogenous Metabolite
|
Neurological Disease
|
|
Hypotaurine (2-aminoethanesulfinic acid), an intermediate in taurine biosynthesis from cysteine in astrocytes, is an endogenous inhibitory amino acid of the glycine receptor. Antioxidant .
|
-
-
- HY-P990110
-
|
Mab158
|
Amyloid-β
|
Neurological Disease
|
|
Lecanemab (Mouse IGG2a) (Mab158) is a monoclonal antibody that targets soluble β-amyloid and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IGG2a sequence. Lecanemab (Mouse IGG2a) almost abolishes Aβ accumulation in astrocytes and rescues neurons from Aβ-induced cell death. Lecanemab (Mouse IGG2a) holds promise for research in the field of Alzheimer's disease .
|
-
-
- HY-B0712B
-
|
Ro 13-9904
|
Antibiotic
GSK-3
Bacterial
Aurora Kinase
|
Infection
Inflammation/Immunology
Cancer
|
|
Ceftriaxone sodium salt (Ro 13-9904) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium salt is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone sodium salt is an inhibitor of Aurora B. Ceftriaxone sodium salt has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium salt can be used in the study of bacterial infections and meningitis .
|
-
-
- HY-B1614
-
-
-
- HY-N0474
-
-
-
- HY-B0712
-
|
Ro 13-9904 free acid
|
Bacterial
Antibiotic
GSK-3
Aurora Kinase
|
Infection
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis .
|
-
-
- HY-101878
-
|
Sulforhodamine 101; SR101
|
Fluorescent Dye
|
Neurological Disease
|
|
Texas Red (Sulforhodamine 101) is an amphoteric rhodamine red fluorescent dye (excitation/emission: 586/605 nm). Texas Red is used extensively for investigating neuronal morphology and acts as acell type-selective fluorescent marker of astrocytes bothin vivoand in slice preparations .
|
-
-
- HY-P1410A
-
GsMTx4 TFA
Maximum Cited Publications
112 Publications Verification
|
TRP Channel
Piezo Channel
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
GsMTx4 TFA is a spider venom peptide that selectively inhibits cationic-permeable mechanosensitive channels (MSCs) belonging to the Piezo and TRP channel families. GsMTx4 TFA also blocks cation-selective stretch-activated channels (SACs) , attenuates lysophosphatidylcholine (LPC)-induced astrocyte toxicity and microglial reactivity. GsMTx4 TFA is an important pharmacological tool for identifying the role of these excitatory MSCs in normal physiology and pathology .
|
-
-
- HY-101374A
-
|
(+)-BRD4780
|
Imidazoline Receptor
Caspase
Mitochondrial Metabolism
Lactate Dehydrogenase
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
AGN 192403 (BRD4780) hydrochloride is a potent and selective imidazoline-1 receptor antagonist with a Ki value of 42 nM. AGN 192403 hydrochloride is also a TMED9 inhibitor. AGN 192403 hydrochloride shows protective effects on oxidative cytotoxicity and mitochondrial inhibitor-induced cytotoxicity in astrocytes. AGN 192403 hydrochloride mitigates the proliferation and migration of differentiated glioma tumor cells. AGN 192403 hydrochloride can be used for glioma tumor and neurological diseases research .
|
-
-
- HY-107661
-
|
ONO-2506; (R)-2-Propyloctanoic acid
|
ERK
Akt
NF-κB
EAAT
|
Cardiovascular Disease
Neurological Disease
|
|
Arundic Acid is an orally effective astrocyte function modulator and neuroprotective agent. Arundic Acid increases the expression and function of the astrocytic glutamate transporter EAAT1 by activating the ERK, Akt and NF-κB pathways. Arundic Acid attenuates retinal ganglion cell death in a normal-tension glaucoma model. Arundic Acid exerts neuroprotective effects in a mouse model of Parkinson's disease. Arundic Acid is a S100β protein synthesis inhibitor that prevents neurological deficits and brain tissue damage after intracerebral hemorrhage in rats. Arundic Acid downregulates neuroinflammation and astrocytic dysfunction after status epilepticus in immature rats. Arundic Acid is applicable to research related to Parkinson's disease, cerebral ischemia, glaucoma, intracerebral hemorrhage and epilepsy .
|
-
-
- HY-15515
-
|
|
Na+/Ca2+ Exchanger
|
Cardiovascular Disease
|
|
SEA0400 is a novel and selective inhibitor of the Na +-Ca 2+ exchanger (NCX), inhibiting Na +-dependent Ca 2+ uptake in cultured neurons, astrocytes, and microglia with IC50s of from 5 to 33 nM.
|
-
-
- HY-14993
-
|
|
Protease Activated Receptor (PAR)
Apoptosis
|
Cardiovascular Disease
|
|
SCH79797 is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC50 of 70 nM and a Ki of 35 nM. SCH79797 inhibits thrombin-induced platelet aggregation with an IC50 of 3 μM. SCH79797 has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes .
|
-
-
- HY-D0889
-
|
Gly-Gly; H-Gly-Gly-OH
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Glycylglycine is a non-selective glycylglycine dipeptidase substrate and iNOS inhibitor. Glycylglycine can cross the cell membrane by passive diffusion and is hydrolyzed to glycine in the cell, participating in energy metabolism and antioxidant processes. Glycylglycine promotes spermatogonial stem cells (SSCs) proliferation, inhibits astrocyte overactivation and reduces nitric oxide (NO) release, while upregulating the expression of neurotrophic factors (such as PDGFA, FGF2, CNTF) to support nerve myelin repair. Glycylglycine can be used to study male reproductive biology (such as SSCs proliferation regulation) and neurodegenerative diseases (such as neuroprotective mechanisms in multiple sclerosis) .
|
-
-
- HY-117727
-
|
MIN-102; Hydroxypioglitazone
|
PPAR
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Leriglitazone (MIN-102; Hydroxypioglitazone) is an orally active and a BBB-penetrable PPARγ agonist with an EC50 of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases .
|
-
-
- HY-N0493
-
|
|
COX
Lipoxygenase
NF-κB
p38 MAPK
ERK
HIF/HIF Prolyl-Hydroxylase
Keap1-Nrf2
PI3K
Apoptosis
Autophagy
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Pectolinarigenin is an orally active dual inhibitor of COX-2/5-LOX with anti-inflammatory, antioxidant, antitumor and neuroprotective activities. Pectolinarigenin exerts neuroprotective and anti-inflammatory effects on astrocyte inflammation via the NFκB and MAPK pathways. Pectolinarigenin inhibits LPS-induced phosphorylation of ERK1/2, N-FκB and p38MAPK, directly inhibits the enzymatic activity or binding of COX-2, 5-LOX and HIF-1α, and reduces the level of XIAP. Pectolinarigenin modifies Keap1 to promote nuclear accumulation of Nrf2, induces ARE-mediated antioxidant enzyme expression, and possesses direct free radical scavenging activity. Pectolinarigenin reduces the release of NO, proinflammatory mediators and leukotrienes, and increases the level of IL-10. Pectolinarigenin induces G2/M cell cycle arrest, apoptosis (Apoptosis) and autophagy (Autophagy) via the PI3K/AKT/mTOR signaling pathway. Pectolinarigenin reduces renal crystal deposition and inhibits melanin synthesis. Pectolinarigenin inhibits inflammation and alleviates allergy in mouse models of inflammation. Pectolinarigenin alleviates renal injury, inflammation and oxidative stress in mice by inhibiting HIF-1α activity. Pectolinarigenin can be used for the research of neurodegenerative diseases, inflammatory/allergic diseases, calcium oxalate nephrocalcinosis, gastric cancer, melasma, post-inflammatory diseases and chloasma .
|
-
-
- HY-P1146
-
Semax
1 Publications Verification
|
Amyloid-β
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Semax is a BBB-penetrable adrenocorticotropic hormone-like peptide and can form stable complexes with Cu 2+. Semax is a synthetic peptide analog of Adrenocorticotropic hormone (ACTH) (4-10). Semax has immunomodulatory, nootropic and neuroprotective activities. Semax can be used in the research of central nervous system diseases such as Alzheimer's disease and cerebral ischemia .
|
-
-
- HY-NP0204
-
|
|
ELOVL
Apoptosis
NOD-like Receptor (NLR)
Caspase
Tau Protein
|
Neurological Disease
Inflammation/Immunology
|
|
Mouse Serum Albumin is most abundant protein in plasma, which leaks into the brain parenchyma when the blood-brain barrier (BBB) is impaired. Mouse Serum Albumin induces astrocytes to A1 phenotype to remarkably increase levels of Elovl1. Mouse Serum Albumin promotes VLSFAs secretion and causes neuronal lippoapoptosis through endoplasmic reticulum stress response pathway. MSA-activated microglia triggeres remarkable tau phosphorylation at multiple sites (Ser202/Thr205) through NLRP3 inflammasome pathway. Mouse Serum Albumin decreases the spatial learning and memory abilities in mice. Mouse Serum Albumin can be used for the study of neurodegenerative diseases like Alzheimer’s disease (AD) and frontotemporal dementia (FTD) .
|
-
-
- HY-107744
-
-
-
- HY-136341
-
-
-
- HY-160955
-
|
|
Phosphatase
|
Neurological Disease
|
|
Z218484536 is a selective and brain-penetrant phosphoserine phosphatase (PSPH) inhibitor. Z218484536 binds to PSPH with a Kd value of approximately 0.23 μM. Z218484536 reduces L-serine and D-serine levels in astrocytes. Z218484536 is able to suppress spontaneous epileptic seizures without causing serious side effects. Z218484536 also shows good anti-epileptic effects in the temporal lobe epilepsy (TLE) model .
|
-
-
- HY-14994
-
|
|
Protease Activated Receptor (PAR)
Apoptosis
|
Cardiovascular Disease
|
|
SCH79797 dihydrochloride is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 dihydrochloride inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC50 of 70 nM and a Ki of 35 nM. SCH79797 dihydrochloride inhibits thrombin-induced platelet aggregation with an IC50 of 3 μM. SCH79797 dihydrochloride has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 dihydrochloride also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes .
|
-
-
- HY-N0061
-
|
|
Reactive Oxygen Species (ROS)
|
Neurological Disease
|
|
Ethyl ferulate, a naturally lipophilic derivative of ferulic acid originally derived from Rhizoma Chuanxiong, induces heme oxygenase-1 (HO-1) and protects rat neurons against oxidative stress . Ethyl ferulate also protects neurons against amyloid β peptide (1-42)-induced oxidative stress and neurotoxicity .
|
-
-
- HY-P3394
-
|
CTB, from vibrio cholerae
|
Biochemical Assay Reagents
|
Others
|
|
Cholera toxin B subunit, from vibrio cholerae (CTB, from vibrio cholerae) is non-toxic to cells and possesses no intrinsic adenylate cyclase activity. Cholera toxin B subunit, from vibrio cholerae attaches to cells by binding to ganglioside GM1.8 CTB has been shown to be a good label for microglial cells (due to the enrichment of ganglioside GM1 on their cell surface), but not for oligodendrocytes or astrocytes. Cholera toxin B subunit, from vibrio cholerae has been reported to be an excellent tracer for the study of axonal transport using immunohistochemical methods. Cholera toxin B subunit, from vibrio cholerae has been widely used as a marker of membrane lipid rafts .
|
-
-
- HY-B0712A
-
|
Ro 13-9904 sodium hydrate
|
Bacterial
Antibiotic
GSK-3
Aurora Kinase
|
Infection
Cancer
|
|
Ceftriaxone sodium hydrate (Ro 13-9904 sodium hydrate) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium hydrate is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone sodium hydrate is an inhibitor of Aurora B. Ceftriaxone sodium hydrate has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium hydrate can be used in the study of bacterial infections and meningitis .
|
-
-
- HY-121362
-
|
|
Bacterial
Endogenous Metabolite
TrxR
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Evernic Acid is an orally active thioredoxin reductase 1 (TrxR1) inhibitor and antiproliferative agent. Evernic Acid inhibits the proliferation and migration of human breast cancer cells. Evernic Acid blocks the NF-κB pathway by inhibiting p65 nuclear translocation and IκBα phosphorylation, thereby suppressing downstream inflammatory mediators. Evernic Acid acts as an antioxidant, anti-inflammatory agent and neuroprotective agent, protects neurons from cell death, mitochondrial dysfunction and oxidative stress damage, reduces astrocyte activation, and ameliorates dopaminergic neuron loss and neuroinflammation. Evernic Acid inhibits enoyl reductases FabI and FabZ of Plasmodium falciparum. Evernic Acid downregulates the expression of lasB and rhlA genes in Pseudomonas aeruginosa, inhibits quorum sensing and biofilm formation, and exerts antibacterial activity against Gram-positive bacteria, Gram-negative bacteria and fungi. Evernic Acid is applicable to research related to breast cancer, Parkinson's disease, bacterial infections and fungal infections .
|
-
-
- HY-N0167
-
|
Ginsenoside C-Mx1; Gypenoside IX
|
p38 MAPK
Akt
NF-κB
COX
Interleukin Related
NO Synthase
|
Metabolic Disease
Inflammation/Immunology
|
|
Gynostemma Extract (Gypenoside IX) is a triterpenoid saponin. Gynostemma Extract can be isolated from Panax notoginseng. Gynostemma Extract reduces NFκB nuclear translocation and transcriptional activity by inhibiting the p38 MAPK/Akt/NFκB signaling pathway. Gynostemma Extract reduces the expression of cytokines (COX-2, IL-6) and the production of NO. Gynostemma Extract has anti-inflammatory activity. Gynostemma Extract can be used in the study of liver injury and neuroinflammation .
|
-
-
- HY-145990
-
|
MF6
|
FABP
|
Inflammation/Immunology
|
|
FABPs ligand 6 (MF6) is an FABP5 and FABP7 inhibitor with KD values of 874 nM and 20 nM, respectively. FABPs ligand 6 can be used for multiple sclerosis research .
|
-
-
- HY-113468A
-
|
3-Methoxy-L-tyrosine; 3-O-Methyl-L-DOPA
|
Drug Derivative
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease .
|
-
-
- HY-107521
-
|
CF3-Bza-TBOA
|
EAAT
|
Neurological Disease
|
|
TFB-TBOA (CF3-Bza-TBOA) is a potent glutamate transporter blocker that potently suppresses the activity of glial transporters. TFB-TBOA shows IC50 values of 22, 17, and 300 nM for glutamate transporters EAAT1, EAAT2, and EAAT3 respectively in an uptake assay using cells transiently expressing EAATs .
|
-
-
- HY-113489
-
|
14,15-EET
|
Endogenous Metabolite
|
Cardiovascular Disease
Neurological Disease
|
|
14,15-Epoxyeicosatrienoic acid (14,15-EET) is a metabolite of Arachidonic acid (HY-109590). 14,15-Epoxyeicosatrienoic acid is a potent inhibitor of in vivo platelet aggregation. 14,15-Epoxyeicosatrienoic acid facilitates astrocytic Aβ clearance. 14,15-Epoxyeicosatrienoic acid can be used for Alzheimer's Disease research .
|
-
-
- HY-N7526
-
|
DHNQ; 5,8-Dihydroxy-1,4-naphthoquinone
|
Apoptosis
Autophagy
PI3K
Akt
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Naphthazarin (DHNQ) is a microtubule depolymerizing agent. Naphthazarin can improve motor function and reduce neuroinflammation in mouse models of Parkinson's disease. Naphthazarin can induce tumor cell apoptosis, autophagy, and cell cycle arrest. Naphthazarin can also induce erythrocyte apoptosis. Naphthazarin can be used in the research of tumors and neurodegenerative diseases .
|
-
-
- HY-121035
-
|
7-Bromoindirubin-3-Oxime
|
CDK
GSK-3
|
Neurological Disease
|
|
7BIO (7-Bromoindirubin-3-Oxime) is the derivate of indirubin. 7BIO (7-Bromoindirubin-3-Oxime) has inhibitory effects against cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3β (GSK3β). 7BIO (7-Bromoindirubin-3-Oxime) inhibits Aβ oligomer-induced neuroinflammation, synaptic impairments, tau hyper-phosphorylation, activation of astrocytes and microglia, and attenuates Aβ oligomer-induced cognitive impairments in mice [1].
|
-
-
- HY-129079
-
-
-
- HY-P1146A
-
|
|
Amyloid-β
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Semax acetate is a BBB-penetrable adrenocorticotropic hormone-like peptide and can form stable complexes with Cu 2+. Semax acetate is a synthetic peptide analog of Adrenocorticotropic hormone (ACTH) (4-10). Semax acetate has immunomodulatory, nootropic and neuroprotective activities. Semax acetate can be used in the research of central nervous system diseases such as Alzheimer's disease and cerebral ischemia .
|
-
-
- HY-113468AS
-
|
3-Methoxy-L-tyrosine-d3; 3-O-Methyl-L-DOPA-d3
|
Isotope-Labeled Compounds
Drug Metabolite
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
3-O-Methyldopa-d3 (3-Methoxy-L-tyrosine-d3) is deuterium labeled 3-O-Methyldopa (HY-113468A). 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease .
|
-
-
- HY-P10019
-
|
NLY01
|
GCGR
|
Neurological Disease
Inflammation/Immunology
|
|
Pegsebrenatide (NLY01) is a blood-brain barrier-penetrant GLP-1R agonist. Pegsebrenatide alleviates retinal inflammation and neuronal death secondary to ocular hypertension . Pegsebrenatide significantly delays onset and reduces disease severity in experimental autoimmune encephalomyelitis . Pegsebrenatide inhibits the formation of A1 reactive astrocytes in nerve cells and reduces the loss of retinal ganglion cells and dopaminergic neurons. Pegsebrenatide exerts neuroprotective effects in a mouse model of Parkinson's disease by directly preventing microglia-mediated conversion of astrocytes to the A1 neurotoxic phenotype. Pegsebrenatide can be used for research on glaucoma, Parkinson's disease, and multiple sclerosis .
|
-
-
- HY-120920
-
|
|
Dopamine Receptor
|
Inflammation/Immunology
|
|
UNC9995 is a β-arrestin2-biased agonist of dopamine receptor Drd2. UNC9995 inhibits NLRP3 inflammasome activation by enhancing β-arrestin2-NLRP3 interaction, thus prevents neuronal degeneration. Futhermore, UNC9995 activates the Drd2/β-arrestin2 signaling to prevent inflammation-related genes transcription-induced by JAK/STAT3. UNC9995 improves depressive behavior in mouse model, and improves astrocytes dysfunctions .
|
-
-
- HY-101960A
-
|
AG-183
|
EGFR
|
Cancer
|
|
Tyrphostin A51 is a potent protein tyrosine kinase (PTK) inhibitor. Tyrphostin A51 inhibits the volume-dependent release of [ 3H]taurine in a dose-dependent manner. Tyrphostin A51 markedly reduces cellular tyrosyl phosphorylation level. Tyrphostin A51 inhibits both basal and EGF-induced human bone cell proliferation .
|
-
-
- HY-115498
-
|
|
Apoptosis
NO Synthase
Interleukin Related
COX
|
Neurological Disease
Inflammation/Immunology
|
ARN14494 is a potent and selective serine palmitoyltransferase (SPT) inhibitor, with an IC50 of 27.3 nM. ARN14494 affects the CNS in terms of anti-inflammation and neuroprotection. ARN14494 protects neurons from β-amyloid 1-42-induced neurotoxicity through a variety of mechanisms, including anti-oxidation, anti-apoptosis, and anti-inflammation. ARN14494 can be used for Alzheimer’s disease research .
|
-
-
- HY-B0764B
-
|
Dibutyryl cAMP; DBcAMP
|
PKA
Reactive Oxygen Species (ROS)
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
|
-
-
- HY-N0092R
-
|
|
Reference Standards
Adenosine Receptor
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
Inosine (Standard) is the analytical standard of Inosine. This product is intended for research and analytical applications. Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A1 (A1R) and A2A (A2AR) receptors . In Vitro:Inosine dose-dependently stimulates cAMP production mediated through the A2AR .
Inosine dose-dependently induces hA2AR-mediated ERK1/2 phosphorylation .
Inosine (100 μM; 24 hours) reduces oxidative stress in MES 23.5 cells cultured with astrocytes .
In Vivo:Inosine (10-100 mg/kg; i.p.) exhibits antinociceptive effect in mice .
|
-
-
- HY-P10557
-
|
|
Biochemical Assay Reagents
|
Neurological Disease
|
|
DAG peptide is a cyclic peptide. DAG peptide selectively recognizes a subset of astrocytes that are activated in Alzheimer's disease (AD) starting at an early stage of the disease. DAG peptide can be used as a tool to enhance the delivery of therapeutics and imaging agents to sites of vascular changes and astrogliosis in diseases associated with neuroinflammation .
|
-
-
- HY-N0474R
-
|
|
Reference Standards
NF-κB
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Tyrosol (Standard) is the analytical standard of Tyrosol. This product is intended for research and analytical applications. Tyrosol is a derivative of phenethyl alcohol. Tyrosol attenuates pro-inflammatory cytokines from cultured astrocytes and NF-κB activation. Anti-oxidative and anti-inflammatory effects .
|
-
-
- HY-D2155
-
|
|
Fluorescent Dye
|
Others
|
|
Texas red-X 4-succinimidyl ester is a derivative of Texas Red (HY-101878), an amphoteric rhodamine red fluorescent dye. Texas Red is widely used to study neuronal morphology and as a cell type-selective fluorescent marker for astrocytes, both in vivo and in slice preparations.
|
-
-
- HY-130354
-
|
Bt2cGMP sodium
|
Potassium Channel
|
Cardiovascular Disease
|
|
Dibutyryl-cGMP sodium (Bt2cGMP sodium) is a cell-permeable cGMP analogue. Dibutyryl-cGMP sodium preferentially activates cGMP-dependent protein kinase (PKG). Dibutyryl-cGMP sodium inhibits the release of [ 3H]-arachidonic acid from γ thrombin-stimulated human platelets. Dibutyryl-cGMP sodium induces peripheral antinociception via activation of ATP-sensitive K + channels .
|
-
-
- HY-D0889R
-
|
Gly-Gly (Standard); H-Gly-Gly-OH (Standard)
|
Reference Standards
Endogenous Metabolite
|
Metabolic Disease
|
|
Glycylglycine (Standard) is the analytical standard of Glycylglycine (HY-D0889). This product is intended for research and analytical applications. Glycylglycine is a non-selective glycylglycine dipeptidase substrate and iNOS inhibitor. Glycylglycine can cross the cell membrane by passive diffusion and is hydrolyzed to glycine in the cell, participating in energy metabolism and antioxidant processes. Glycylglycine promotes spermatogonial stem cells (SSCs) proliferation, inhibits astrocyte overactivation and reduces nitric oxide (NO) release, while upregulating the expression of neurotrophic factors (such as PDGFA, FGF2, CNTF) to support nerve myelin repair. Glycylglycine can be used to study male reproductive biology (such as SSCs proliferation regulation) and neurodegenerative diseases (such as neuroprotective mechanisms in multiple sclerosis) .
|
-
-
- HY-149295
-
|
|
PROTACs
Estrogen Receptor/ERR
Apoptosis
|
Cancer
|
|
PROTAC ERα Degrader-4 (Compound ZD12) is a highly potent and selectivePROTAC ERα degrader (Ki: 5.08 μM). PROTAC ERα Degrader-4 contains OBHSAs, linker and E3 ligase ligands. PROTAC ERα Degrader-4 shows excellent cell inhibitory and ERα degradation activity against Tamoxifen-sensitive and -resistant ER + breast cancer (BC) cells and ERα-mutated BC cells. PROTAC ERα Degrader-4 can induce apoptosis and can be used for cancer research.
|
-
-
- HY-DY1056
-
|
|
Fluorescent Dye
|
Neurological Disease
|
Texas Red (Sulforhodamine 101) (solution) is an amphoteric rhodamine red fluorescent dye (excitation/emission: 586/605 nm). Texas Red is used extensively for investigating neuronal morphology and acts as acell type-selective fluorescent marker of astrocytes bothin vivoand in slice preparations .
Solvent and concentration: DMSO: 10 mM
The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.
|
-
-
- HY-131139A
-
|
|
Apoptosis
|
Neurological Disease
Cancer
|
|
Ganglioside GD3 diammonium is an acidic glycosphingolipid. Ganglioside GD3 diammonium inhibits the proliferation of cancer cells, affects the opening of the mitochondrial permeability transition pore (PTPC), induces apoptosis and activates caspase family. Ganglioside GD3 diammonium can be used in research about cancer and neurodegenerative diseases .
|
-
- HY-114095
-
-
- HY-B0712R
-
|
Ro 13-9904 free acid (Standard)
|
Reference Standards
Bacterial
Antibiotic
GSK-3
Aurora Kinase
|
Infection
Inflammation/Immunology
Cancer
|
|
Ceftriaxone (Standard) is the analytical standard of Ceftriaxone. This product is intended for research and analytical applications. Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis[1][2][3][4][5][6][7].
|
-
- HY-101374
-
-
- HY-149234
-
|
|
Monoamine Oxidase
|
Neurological Disease
|
|
MAO-B-IN-18 is a potent and selective MAO B inhibitor with IC50s of 52 nM and 14 μM for hMAO B and hMAO A, respectively. MAO-B-IN-18 enables promising cytoprotective effects against hydrogen peroxide insults in neuroblastoma and astrocytes cultures .
|
-
- HY-115708
-
|
Cer(t18:0/22:0); Ceramide (t18:0/22:0); C22 Phytosphingosine (t18:0/22:0)
|
Endogenous Metabolite
|
Metabolic Disease
|
|
C22 Phytoceramide is a sphingolipid that has been found in Moro blood orange (C. sinensis) peels. It has also been found in primary human astrocytes.
|
-
- HY-152472
-
|
|
Trk Receptor
|
Neurological Disease
|
|
ENT-C225 is an effective activator of TrkB neurotrophin receptor. ENT-C225 has high effect on activating TrkB receptor (TrkBR), and has good physicochemical properties and neuroprotective properties .
|
-
- HY-15515R
-
|
|
Na+/Ca2+ Exchanger
Reference Standards
|
Cardiovascular Disease
|
|
SEA0400 (Standard) is the analytical standard of SEA0400. This product is intended for research and analytical applications. SEA0400 is a novel and selective inhibitor of the Na+-Ca2+ exchanger (NCX), inhibiting Na+-dependent Ca2+ uptake in cultured neurons, astrocytes, and microglia with IC50s of from 5 to 33 nM.
|
-
- HY-131139
-
|
|
Apoptosis
|
Neurological Disease
Cancer
|
|
Ganglioside GD3 disodium salt is an acidic glycosphingolipid. Ganglioside GD3 disodium salt inhibits the proliferation of cancer cells, affects the opening of the mitochondrial permeability transition pore (PTPC), induces apoptosis and activates caspase family. Ganglioside GD3 disodium salt can be used in research about cancer and neurodegenerative diseases .
|
-
- HY-151919
-
|
|
FAAH
|
Inflammation/Immunology
|
|
FAAH-IN-7 is a reversible and potent FAAH inhibitor with an IC50 value of 8.29 nM. FAAH-IN-7 suppresses oxidative stress in 1321N1 astrocytes and exhibits notable neuroprotective effect in ex vivo neuroinflammation model .
|
-
- HY-10996
-
|
|
FGFR
|
Neurological Disease
|
|
KHS101 is a small molecule that accelerates neuronal differentiation. KHS101 can distributes to the brain and resulted in a significant increase in neuronal differentiation .
|
-
- HY-163801
-
|
|
Nuclear Hormone Receptor 4A/NR4A
|
Neurological Disease
|
|
Nurr1 agonist 9 (Compound 36) is an agonist for Nurr1 with an EC50 of 0.090 µM and a Kd of 0.17 µM. Nurr1 agonist 9 activates the Nurr1 homodimer (NurRE, EC50=0.094 µM) and the Nurr1-RXR heterodimer (DR5, EC50=0.165 µM). Nurr1 agonist 9 induces the expression of Nurr1-regulated tyrosine hydroxylase (TH) in organoid Parkinson's Disease model. Nurr1 agonist 9 is human brain endothelial cell barrier prmeable .
|
-
- HY-115708S
-
-
- HY-179214
-
|
|
Glycosidase
Amyloid-β
NF-κB
Interleukin Related
|
Neurological Disease
|
|
DEL-C1 is a CHI3L1 inhibitor. DEL-C1 can restore the ability to clear Amyloid-β and repair lysosomal function of astrocytes. DEL-C1 can inhibit NF-κB signaling and IL-6 secretion. DEL-C1 can be used for the researches of inflammation and neurological disease, such as Alzheimer's disease .
|
-
- HY-101960
-
|
(Z)-AG-183
|
EGFR
|
Others
|
|
(Z)-Tyrphostin A51 is the Z configuration of Lanoconazole A51. Tyrphostin A51 is a potent protein tyrosine kinase (PTK) inhibitor. Tyrphostin A51 inhibits the volume-dependent release of [ 3H]taurine in a dose-dependent manner. Tyrphostin A51 markedly reduces cellular tyrosyl phosphorylation level. Tyrphostin A51 inhibits both basal and EGF-induced human bone cell proliferation .
|
-
- HY-149542
-
|
|
Tau Protein
Apoptosis
GSK-3
|
Neurological Disease
|
|
GSK-3β inhibitor 15 (Compound 54) is a GSK-3β inhibitor (IC50: 3.4 nM). GSK-3β inhibitor 15 inhibits Aβ1-42-induced GSK-3β and tau protein phosphorylation. GSK-3β inhibitor 15 inhibits LPS-induced iNOS expression. GSK-3β inhibitor 15 has neuroprotective effects on Aβ1-42-induced neurotoxicity. GSK-3β inhibitor 15 can be used for research of Alzheimer’s disease (AD) .
|
-
- HY-14993R
-
|
|
Protease Activated Receptor (PAR)
Apoptosis
|
Cardiovascular Disease
|
|
SCH79797 (Standard) is the analytical standard of SCH79797. This product is intended for research and analytical applications. SCH79797 is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC50 of 70 nM and a Ki of 35 nM. SCH79797 inhibits thrombin-induced platelet aggregation with an IC50 of 3 μM. SCH79797 has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes .
|
-
- HY-B0712S1
-
|
Ro 13-9904-13C2,d32 triethylammonium salt
|
Antibiotic
Aurora Kinase
GSK-3
Bacterial
Isotope-Labeled Compounds
|
Infection
Inflammation/Immunology
Cancer
|
|
Ceftriaxone-13C2,d3 triethylammonium salt is 13C and deuterated labeled Ceftriaxone (HY-B0712). Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 mM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis .
|
-
- HY-108654
-
|
|
P2Y Receptor
Apoptosis
|
Neurological Disease
|
|
PSB 0474 (3-phenacyl-UDP) is a selective and potent P2Y6 receptor agonist with an EC50 of 70 nM . PSB 0474 inhibits cell proliferation, increases NO release in astrocytes and microglia cells. PSB 0474 induces astrocytes apoptosis .
|
-
- HY-B1558
-
|
MCI-2016 free base
|
Calcium Channel
|
Neurological Disease
|
|
Bifemelane is a nootropic compound. Bifemelan causes the first peak by stimulating release from intracellular Ca 2+ stores and the second by capacitive entry through store–operated Ca 2+ channels. Bifemelane will be provided as a pharmacological tool for basic studies on astrocytes .
|
-
- HY-147789
-
|
|
Akt
|
Neurological Disease
Cancer
|
|
FPDT is an anti-glioblastoma agent. FPDT displays the IC50 value of 45–68 μM for GBM cells and >100 μM for astrocytes. Anti-glioblastoma activity of FPDT is linked to downregulation of the AKT pathway .
|
-
- HY-118489
-
|
|
iGluR
|
Neurological Disease
Inflammation/Immunology
|
|
L644711 is an anion transport inhibitor that reduces cell swelling by inhibiting potassium-activated D-aspartate release in astrocytes. L644711 can be used in the study of brain injury and neuroprotection .
|
-
- HY-B1614R
-
|
NAB-365 hydrochloride (Standard)
|
Reference Standards
Adrenergic Receptor
|
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
|
Clenbuterol (hydrochloride) (Standard) is the analytical standard of Clenbuterol (hydrochloride). This product is intended for research and analytical applications. Clenbuterol (NAB-365) hydrochloride, a selective β2-adrenergic agonist, enhances skeletal muscle strength and hypertrophy. Clenbuterol hydrochloride induces growth factor mRNA, activates astrocytes, and protects rat brain tissue against ischemic damage .
|
-
- HY-118207
-
|
|
GABA Receptor
|
Cancer
|
|
LU-32-176B, a GABA transporter 1(GAT1) selective inhibitor, is found to exert a synergistic anticonvulsant action with GAT2 transport inhibitor EF1502. LU-32-176B inhibits neurons, astrocytes and mGAT1 with the IC50 values of 2μM, 1μM, 4μM, respectively .
|
-
- HY-10282
-
|
|
Endothelin Receptor
|
Others
|
|
Daglutril is a compound with the potential to regulate cytokine-induced endothelin-1 production in astrocytes. In studies, it has an inhibitory effect on the production of endothelin-1 induced by some cytokines and can be used as a tool to screen compounds that inhibit endothelin-1 production in astrocytes.
|
-
- HY-107661A
-
|
(S)ONO-2506; (S)-2-Propyloctanoic acid
|
Drug Isomer
|
Others
|
|
S-(+)-Arundic Acid ((S)ONO-2506) is the S-enantiomer of Arundic Acid. Arundic acid is an astrocyte-modulating agent, has the potential for stroke and Alzheimer’s disease research .
|
-
- HY-100803R
-
|
2-Aminoethanesulfinic acid (Standard)
|
Reference Standards
Endogenous Metabolite
|
Neurological Disease
|
|
Hypotaurine (Standard) is the analytical standard of Hypotaurine. This product is intended for research and analytical applications. Hypotaurine (2-aminoethanesulfinic acid), an intermediate in taurine biosynthesis from cysteine in astrocytes, is an endogenous inhibitory amino acid of the glycine receptor. Antioxidant[1].
|
-
- HY-N8713
-
|
|
Reactive Oxygen Species (ROS)
|
Neurological Disease
|
|
4-Methyl-6-phenyl-2H-pyranone can be used for the synthesis of N-hydroxypyridone derivatives, which can protect astrocytes against hydrogen peroxide-induced toxicity via improved mitochondrial functionality .
|
-
- HY-W753375R
-
|
|
Reference Standards
Fungal
Succinate Dehydrogenase
|
Infection
|
|
Clenbuterol (hydrochloride) (Standard) is the analytical standard of Clenbuterol (hydrochloride). This product is intended for research and analytical applications. Clenbuterol (NAB-365) hydrochloride, a selective β2-adrenergic agonist, enhances skeletal muscle strength and hypertrophy. Clenbuterol hydrochloride induces growth factor mRNA, activates astrocytes, and protects rat brain tissue against ischemic damage .
|
-
- HY-149538
-
|
|
Potassium Channel
|
Neurological Disease
|
|
TWIK-1/TREK-1-IN-3 (compound 2h) is an inhibitor of TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 9.74 μM and 16.5 μM, respectively, and has antidepressant-like effects .
|
-
- HY-149300
-
|
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
SB-1436 is an Cholinesterase (ChE) inhibitor, inhibits acetylcholinesterase (AChE), butyrylcholinesterase (BChE) and recombinant human acetylcholinesterase (rHuAChE) with IC50s of 0.176, 0.37 and 0.08 μM, respectively. SB-1436 inhibits AChE and BChE in a non-competitive manner with Kis of 0.046 and 0.115 μM, respectively. SB-1436 significantly stops the self-aggregation of Aβ, and can be used for neurological disease research .
|
-
- HY-136341R
-
|
|
Reference Standards
Apoptosis
NO Synthase
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
|
Sanguinarine (Standard) is the analytical standard of Sanguinarine. This product is intended for research and analytical applications. Sanguinarine (Sanguinarin), a benzophenanthridine alkaloid derived from the root of Sanguinaria Canadensis, can stimulate apoptosis via activating the production of reactive oxygen species (ROS). Sanguinarine-induced apoptosis is associated with the activation of JNK and NF-κB.
|
-
- HY-W040074
-
|
Diglycine hydrochloride hydrate; Gly-Gly (HCl H2O)
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
Glycylglycine hydrochloride hydrate is a non-selective Glycylglycine hydrochloride hydrate dipeptidase substrate and iNOS inhibitor. Glycylglycine hydrochloride hydrate can cross the cell membrane by passive diffusion and is hydrolyzed to glycine in the cell, participating in energy metabolism and antioxidant processes. Glycylglycine hydrochloride hydrate promotes spermatogonial stem cells (SSCs) proliferation, inhibits astrocyte overactivation and reduces nitric oxide (NO) release, while upregulating the expression of neurotrophic factors (such as PDGFA, FGF2, CNTF) to support nerve myelin repair. Glycylglycine hydrochloride hydrate can be used to study male reproductive biology (such as SSCs proliferation regulation) and neurodegenerative diseases (such as neuroprotective mechanisms in multiple sclerosis) .
|
-
- HY-162682
-
-
- HY-100838
-
|
L-CCG III
|
EAAT
|
Neurological Disease
|
|
cis-α-(Carboxycyclopropyl)glycine (L-CCG III) is a potent, competitive glutamate uptake inhibitor. cis-α-(Carboxycyclopropyl)glycine is a substrate of glutamate transporters (GluT) (EC50: 13 μM, 2 μM for EAAT 1 and EAAT 2, respectively). cis-α-(Carboxycyclopropyl)glycine inhibits a Na +-dependent high-affinity L-glutamate uptake in glial plasmalemmal vesicles (GPV) and synaptosomes .
|
-
- HY-113468AS1
-
|
3-Methoxy-L-tyrosine-d3 hydrate; 3-O-Methyl-L-DOPA-d3 hydrate
|
Isotope-Labeled Compounds
Drug Metabolite
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
3-O-Methyldopa-d3 (hydrate) is the deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa (3-Methoxy-L-tyrosine) hydrate is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa hydrate inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa hydrate has certain antidepressant and neuroprotective activities. 3-O-Methyldopa hydrate can be used in the research of nervous system diseases such as depression and Parkinson's disease .
|
-
- HY-14994R
-
|
|
Protease Activated Receptor (PAR)
Apoptosis
|
Cardiovascular Disease
|
|
SCH79797 (dihydrochloride) (Standard) is the analytical standard of SCH79797 (dihydrochloride). This product is intended for research and analytical applications. SCH79797 dihydrochloride is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 dihydrochloride inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC50 of 70 nM and a Ki of 35 nM. SCH79797 dihydrochloride inhibits thrombin-induced platelet aggregation with an IC50 of 3 μM. SCH79797 dihydrochloride has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 dihydrochloride also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes .
|
-
- HY-B0712AR
-
|
Ro 13-9904 sodium hydrate (Standard)
|
Reference Standards
Bacterial
Antibiotic
GSK-3
Aurora Kinase
|
Infection
Cancer
|
|
Ceftriaxone (sodium hydrate) (Standard) is the analytical standard of Ceftriaxone (sodium hydrate). This product is intended for research and analytical applications. Ceftriaxone sodium hydrate (Ro 13-9904 sodium hydrate) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium hydrate is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone sodium hydrate is an inhibitor of Aurora B. Ceftriaxone sodium hydrate has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium hydrate can be used in the study of bacterial infections and meningitis .
|
-
- HY-172586
-
|
|
GSK-3
PKA
|
Neurological Disease
Cancer
|
|
GSK-3α/β-IN-1 is GSK-3α/β inhibitor with IC50 s of 0.265 μM and 0.255 μM for GSK-3α and GSK-3β, respectively. GSK-3α/β-IN-1 also inhibits PKA with an IC50 of 0.188 μM. GSK-3α/β-IN-1 potently inhibits cell viability of three Glioblastoma (GBM) cell lines (IC50 : 3-6 μM, 72 h) with no toxicity to human astrocytes and good metabolic stability. GSK-3α/β-IN-1 has potential CNS activity in all-human blood-brain barrier (BBB) model of GBM .
|
-
- HY-107744R
-
-
- HY-101878R
-
|
Sulforhodamine 101 (Standard); SR101 (Standard)
|
Fluorescent Dye
Reference Standards
|
Neurological Disease
|
|
Texas Red (Standard) is the analytical standard of Texas Red (HY-101878). This product is intended for research and analytical applications. Texas Red (Sulforhodamine 101) is an amphoteric rhodamine red fluorescent dye (excitation/emission: 586/605 nm). Texas Red is used extensively for investigating neuronal morphology and acts as acell type-selective fluorescent marker of astrocytes bothin vivoand in slice preparations .
|
-
- HY-180899
-
|
|
Glycosidase
Amyloid-β
NF-κB
|
Neurological Disease
|
|
CHI3L1-IN-5 (Compound Z17) is a highly selective CHI3L1 inhibitor with a KD value of 6 μM. CHI3L1-IN-5 restores the clearance ability of astrocytes by rejuvenating lysosomal function and Aβ uptake. CHI3L1-IN-5 alleviates neuroinflammation by inhibiting the NF-κB pathway. CHI3L1-IN-5 can be used for research on Alzheimer's disease .
|
-
- HY-183588
-
|
|
EAAT
Reactive Oxygen Species (ROS)
|
Neurological Disease
|
|
HCM-01 is an Excitatory amino acid transporter 2 (EAAT2) activator with oral effectiveness and blood-brain barrier penetration.HCM-01 binds to the allosteric site of EAAT2, increases EAAT2 expression in astrocytes, enhances glutamate-handling capacity, and modulates glutamate homeostasis.HCM-01 acts as an antioxidant, improves oxidative/antioxidative balance and increases total antioxidant capacity. HCM-01 can be used for the research of Alzheimer's disease .
|
-
- HY-W1130456
-
|
|
Liposome
|
Inflammation/Immunology
|
|
Lipid TD5 is an ionizable cationic lipid with a pKa of 7.3. Lipid TD5 can be used to generate lipid nanoparticles (LNPs) to deliver mRNA in vitro and in vivo. Lipid TD5 LNPs can undergo endocytosis in a 5-HT receptor subtype 1A-dependent manner in primary mouse astrocytes .
|
-
- HY-W033027
-
|
|
GABA Receptor
|
Neurological Disease
|
|
BGT1-IN-1 (compound 9) is a potent BGT1 inhibitor with IC50 value of 13.9, 58.3 µM for hBGT1, GAT3, respectively. BGT1-IN-1 shows no cytotoxic. BGT1-IN-1 shows neuroprotective activity .
|
-
- HY-N19845
-
|
|
Drug Derivative
|
Neurological Disease
Cancer
|
|
2′,7-Diacetyltaxol (Compound 3) is an acetylated derivative of Paclitaxel (HY-B0015) and a cytotoxic agent. 2′,7-Diacetyltaxol is isolated from the acetylated fraction of Taxus brevifolia Nutt. 2′,7-Diacetyltaxol exhibits anticancer activity against oral epidermoid carcinoma. 2′,7-Diacetyltaxol is applicable to the research of neurological diseases .
|
-
- HY-180916
-
|
|
Carbonic Anhydrase
Reactive Oxygen Species (ROS)
NOD-like Receptor (NLR)
Apoptosis
|
Neurological Disease
|
|
CAII-IN-11 (Compound A1) is a dual-target compound that contains a hCA II inhibitor (IC₅₀ = 2 nM) portion and a NO donor portion. CAII-IN-11 also has inhibitory activity against hCA IX, hCA XII, and hCA I, with IC50 values of 6, 3, and 152 nM respectively. CAII-IN-11 significantly increases the intracellular cGMP level in human trabecular meshwork cells. CAII-IN-11 reduces the apoptosis of retinal ganglion cells by reducing oxidative stress (ROS levels), inhibiting astrocytes and the NLRP3 inflammasome activation. CAII-IN-11 has hypotensive activity in rabbit models and can be used for the study of glaucoma .
|
-
- HY-182899
-
|
|
PERK
Ras
COX
PD-1/PD-L1
Apoptosis
DNA/RNA Synthesis
Mitochondrial Metabolism
|
Cancer
|
|
DPAP is a p-ERK1/2 inhibitor with an IC50 of 7.85 μM against p-ERK1/2. DPAP inhibits the expression of p-MEK1/2 and disrupts the Ras-ERK signaling pathway. DPAP inhibits the expression of COX-2 in nerve cells. DPAP damages DNA and mitochondria, induces Apoptosis via the mitochondrial pathway, and upregulates PD-L1. DPAP inhibits melanoma metastasis and angiogenesis, and inactivates spinal microglia and astrocytes. DPAP exhibits anti-melanoma activity and can be combined with anti-PD-1 monoclonal antibodies to modify anti-tumor effects. DPAP is applicable for the research of melanoma .
|
-
- HY-182601
-
|
|
EAAT
Interleukin Related
|
Neurological Disease
|
|
MC-100093 is an orally active, blood-brain barrier-permeable GLT-1 expression upregulator . MC-100093 upregulates the expression of GLT-1 and xCT in rats, and alleviates fentanyl-induced GLT-1 downregulation, IL-6 upregulation and motor hyperactivity. MC-100093 upregulates GLT-1 expression and enhances glutamate uptake in astrocyte-neuron co-culture systems. MC-100093 reduces ethanol consumption and preference, and exerts gender-specific antidepressant-like effects . MC-100093 can be used in studies related to fentanyl overdose, mood disorders and alcohol use disorders .
|
-
- HY-155949
-
|
|
|
Neurological Disease
Cancer
|
|
Bt354 is an orally active STAT3 inhibitor with IC50 values of 4.6 μM (DU145), 6.5 μM (MDA-MB-435) and 7.2 μM (MDA-MB-231), respectively. Bt354 induces cell cycle arrest and apoptosis, and downregulates epithelial-mesenchymal transition-related genes. Bt354 exhibits anti-angiogenic and anti-inflammatory activities, attenuates the polarization of M1 microglia and A1 astrocytes, suppresses inflammasome-related signaling pathways, and alleviates mechanical hyperalgesia and thermal hyperalgesia. Bt354 can be used in research related to glioblastoma multiforme, triple-negative breast cancer, prostate cancer and neuropathic pain .
|
-
- HY-183352
-
|
|
Cholinesterase (ChE)
Toll-like Receptor (TLR)
p38 MAPK
Interleukin Related
Complement System
|
Neurological Disease
|
BuChE-IN-23 is an orally active, blood-brain barrier permeable butyrylcholinesterase (eqBuChE) inhibitor with an IC50 of 15.59 μM and a Ki of 29.33 μM. BuChE-IN-23 exhibits an IC50 of 38.65 μM against hBuChE and shows selectivity for butyrylcholinesterase over acetylcholinesterase. BuChE-IN-23 inhibits LPS (HY-D1056)-induced nitric oxide production, attenuates hippocampal glial cell activation and neuroinflammation, suppresses the TLR4/p38 MAPK signaling pathway, and regulates the IL-1β/C3-mediated microglia-astrocyte inflammatory axis. BuChE-IN-23 can be used for the research of Alzheimer's disease .
|
-
- HY-W049881
-
|
|
Dopamine Receptor
PI3K
Monoamine Oxidase
|
Neurological Disease
|
|
9-Methyl-β-carboline is a monoamine oxidase inhibitor and dopaminergic modulator, with an IC50 of 1 μM against human MAO-A and an IC50 of 15.5 μM against human MAO-B. 9-Methyl-β-carboline possesses cognitive enhancement potential and can cross the blood-brain barrier. 9-Methyl-β-carboline increases dopamine levels by inhibiting monoamine oxidase activity and microglial proliferation. 9-Methyl-β-carboline activates PKA/PKC and mitochondrial respiratory chain complex I, promotes neurotrophic factor expression and reduces α-synuclein (α-synuclein) levels, thereby reversing neurotoxin-induced dopaminergic neuron damage. 9-Methyl-β-carboline also regulates the PI3K pathway and exerts an anti-proliferative effect on astrocytes. 9-Methyl-β-carboline is widely used in Parkinson's disease-related studies .
|
-
- HY-20070
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
BMS-566394 is a selective, orally active TACE (ADAM17) inhibitor. BMS-566394 inhibits LPS-induced TNF-α production in whole blood. BMS-566394 selectively inhibits TACE activity .
|
-
- HY-100788C
-
|
2-(Phosphonomethyl)pentanedioic acid sodium
|
Carboxypeptidase
|
Neurological Disease
|
|
2-PMPA (2-(Phosphonomethyl)pentanedioic acid) sodium is a glutamate carboxypeptidase II (GCPII) inhibitor with an IC50 of 0.0003 μM. 2-PMPA sodium shows low blood-brain barrier penetration. 2-PMPA sodium blocks the hydrolysis of NAAG, regulates glutamate levels in the brain and neurovascular coupling. 2-PMPA sodium is applicable to the research of neurological diseases .
|
-
- HY-181549
-
|
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
Neurological Disease
|
|
PDE4-IN-32 (Compound B05) is a selective, blood-brain barrier permeable PDE4B and PDE4D inhibitor with IC50 values of 13.7 nM and 23.8 nM, respectively. PDE4-IN-32 promotes the recovery of motor and cognitive function in MCAO/R mouse models. PDE4-IN-32 reduces cerebral edema. PDE4-IN-32 can be used for the research of ischemic stroke .
|
-
- HY-142035
-
|
|
Mitochondrial Metabolism
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
N-Propargylglycine is a brain-penetrant and orally active PRODH inhibitor. N-Propargylglycine covalently modifies enzyme-bound FAD and active site lysine, causing enzyme structural distortion, protein decay, and irreversible inhibition of proline and 4-hydroxyproline catabolism. N-Propargylglycine induces UPRmt, upregulates mitochondrial chaperones and YME1L1, enhances mitochondrial proteostasis, blocks astrocytic L-proline consumption, and abolishes L-proline’s ATP-maintaining and viability-protective effects. N-Propargylglycine stimulates neural processes, increases brain proline, hydroxyproline, and sarcosine levels, partially normalizes Huntington’s disease whole brain transcriptomes. N-Propargylglycine reduces hyperoxaluria, prevents calcium oxalate stone formation, reduces kidney tubular damage, and restores weight and survival in Grhpr knockout mice. N-Propargylglycine can be used for the research of breast cancer, neurodegenerative disorders, Huntington’s disease, and primary hyperoxaluria type 2 .
|
-
- HY-183586
-
|
|
Glycosidase
NF-κB
Interleukin Related
|
Neurological Disease
|
|
G721-0377 is a CHI3L1 modulator with a human Kd value of 45 μM. G721-0377 binds to CHI3L1 and modulates downstream signaling pathways. G721-0377 suppresses CHI3L1-induced NF-κB activation, decreases secretion of CHI3L1 and IL-6. G721-0377 can be used for the research of Alzheimer's disease .
|
-
- HY-120380
-
|
|
MOFs
PARP
|
Neurological Disease
|
|
FeTMPyP is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. FeTMPyP inhibits cell death, nitrotyrosine formation, and depolarization of mitochondrial transmembrane potential. FeTMPyP reduces homocysteine-induced nitrosative stress and partially restores TFEB protein and mRNA levels. FeTMPyP improves functional and behavioral deficits caused by chronic constriction injury in rats. FeTMPyP alleviates acute cerebral infarction in a rat model of middle cerebral artery occlusion with mild hyperglycemia. FeTMPyP can be used in studies related to neuropathic pain, renal aging, ischemic penumbra, and hyperglycemic stroke .
|
-
- HY-19667
-
|
DPC 333
|
TNF Receptor
NF-κB
Apoptosis
p38 MAPK
|
Neurological Disease
Inflammation/Immunology
|
|
BMS-561392 (BMS-561392) is a selective ADAM17(TACE) inhibitor. BMS-561392 inhibits TNF-α secretion by regulating signaling pathways such as p44 MAPK and NF-κB. BMS-561392 also affects the survival of central nervous system-related cells including oligodendrocytes and microglia. BMS-561392 promotes microglial apoptosis, enlarges the injury area and exacerbates astrogliosis in a mouse spinal cord injury model. BMS-561392 can be used in research related to spinal cord injury and inflammatory diseases .
|
-
- HY-19667A
-
|
DPC 333 formate
|
TNF Receptor
NF-κB
Apoptosis
p38 MAPK
|
Neurological Disease
Inflammation/Immunology
|
|
BMS-561392 formate (DPC 333 formate) is a selective ADAM17(TACE) inhibitor. BMS-561392 formate inhibits TNF-α secretion by regulating signaling pathways such as p44 MAPK and NF-κB. BMS-561392 formate also affects the survival of central nervous system-related cells including oligodendrocytes and microglia. BMS-561392 formate promotes microglial apoptosis, enlarges the injury area and exacerbates astrogliosis in a mouse spinal cord injury model. BMS-561392 formate can be used in research related to spinal cord injury and inflammatory diseases .
|
-
- HY-B0327
-
|
Dicloguamine
|
Phosphodiesterase (PDE)
NF-κB
AP-1
TRP Channel
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Irsogladine (Dicloguamine) is an orally active gastric mucosal protective agent. Irsogladine inhibits breast cancer recurrence and lung metastasis in nude mice . Irsogladine inhibits the transcriptional activities of NF-κB and AP-1, suppresses the activities of PDE and PDE4 to elevate intracellular cAMP levels, and activates TRPV1 and KATP channels. Irsogladine enhances iNOS expression, NO production, and the activation of cAMP-responsive elements. Irsogladine inhibits the development and progression of intestinal polyps in Apc-mutant mice. Irsogladine alleviates oxidative stress, increases gastric mucosal blood flow, and stimulates the production of endogenous prostaglandins. Irsogladine promotes insulin secretion in MIN6 cells. Irsogladine inhibits tumor angiogenesis, cancer cell proliferation, and the production of proinflammatory cytokines. Irsogladine exerts protective effects on astrocytes in ethanol/hydrochloric acid-induced gastric ulcers in mice. Irsogladine prevents colitis in IL-10 gene-deficient mice by reducing the production of IL-12 and IL-23. Irsogladine upregulates gap junction intercellular communication in pancreatic cancer cells via the PKA pathway. Irsogladine is applicable to research related to breast cancer, intestinal polyposis, gastric ulcer, spontaneous colitis, glioma, liver cancer, and pancreatic cancer [5][6] .
|
-
- HY-181178
-
|
|
Amyloid-β
|
Neurological Disease
|
|
(Mor-Cor)Ag(III) is a blood-brain barrier-penetrant silver(III) corrole complex that penetrates the blood-brain barrier. (Mor-Cor)Ag(III) scavenges reactive oxygen species induced by Aβ42 and disrupts Aβ42 aggregation, attenuating Aβ42-induced neuronal hyperactivity. (Mor-Cor)Ag(III) can be used for the research of Alzheimer's disease .
|
-
- HY-108615
-
|
GPi 819
|
Phosphorylase
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
|
|
CP-316819 (GPi 819) is a blood-brain barrier permeable glycogen phosphorylase inhibitor. CP-316819 inhibits hepatic glycogenolysis, safely reduces blood glucose in type 2 diabetes, and rarely induces hypoglycemia. CP-316819 increases brain glycogen reserves, protects neurons, alleviates hypoglycemic brain injury, and inhibits excessive platelet activation, exerting both neuroprotective and vasculoprotective effects. CP-316819 can be used in research related to hypoglycemia, thrombosis, autoimmune inflammatory diseases, and type 2 diabetes .
|
-
- HY-D3225
-
|
|
Fluorescent Dye
|
Neurological Disease
|
|
MD-B is a •OH Fluorescent probe with blood-brain barrier permeability. MD-B undergoes single-electron oxidation by hydroxyl radicals (•OH), which triggers fluorescence enhancement and enables in-situ imaging of •OH. MD-B allows imaging analysis of hydroxyl radicals (•OH) in the mouse brain, revealing a positive correlation between elevated •OH levels and the severity of depressive phenotypes. MD-B can be used in depression-related research .
|
-
- HY-120267
-
-
- HY-105005
-
|
AAD-2004
|
Prostaglandin Receptor
PGE synthase
Reactive Oxygen Species (ROS)
Apoptosis
|
Neurological Disease
Inflammation/Immunology
|
|
Crisdesalazine (AAD-2004) is a microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor. Crisdesalazine acts as a potent free radical scavenger that directly neutralizes reactive oxygen species (ROS) including hydrogen peroxide, exerting neuroprotective effects against apoptosis and axonal damage. Crisdesalazine inhibits PGE2 production, mediates inflammatory responses, and promotes the conversion of macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype. Crisdesalazine is applicable to neuroprotection research in multiple sclerosis and spinal cord injury .
|
-
- HY-19820A
-
|
|
Akt
Ser/Thr Protease
Apoptosis
MMP
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
NSC45586 sodium is an inhibitor of PHLPP. NSC45586 sodium targets the PP2C phosphatase domains of PHLPP1 and PHLPP2, blocks the phosphatase activity of PHLPP, increases the expression level of FOXO1 in the nucleus, and reduces the protein expression of PHLPP1. NSC45586 sodium activates the AKT survival signaling pathway, enhances IGF-1-induced AKT activation, and inhibits the phosphorylation of AKT/ERK under basal conditions. NSC45586 sodium reduces staurosporine-induced neuronal death, preserves notochord cell morphology and KRT19 expression, inhibits cell apoptosis (apoptosis), improves the viability and proliferation of nucleus pulposus cells, upregulates the expression of ACAN/SOX9, and downregulates the expression of MMP13. NSC45586 sodium binds tightly to bovine serum albumin (bovine serum albumin), and exerts a more significant effect on nucleus pulposus in male individuals. NSC45586 sodium can be used in studies related to global cerebral ischemia and intervertebral disc degeneration .
|
-
- HY-172705
-
|
|
Liposome
nAChR
|
Neurological Disease
|
|
DSPE-PEG2000-RVG29 is a PEG conjugate composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB), crosses the BBB, and mediates receptor-dependent transcytosis. DSPE-PEG2000-RVG29 can be used for brain-targeted drug delivery, surface modification of nanocarriers, as well as gene and nucleic acid delivery. DSPE-PEG2000-RVG29 is applicable to research related to hypoxic-ischemic brain injury, Parkinson's disease, and other conditions .
|
-
- HY-N0493R
-
|
|
Reference Standards
COX
Lipoxygenase
NF-κB
p38 MAPK
ERK
HIF/HIF Prolyl-Hydroxylase
Keap1-Nrf2
PI3K
Apoptosis
Autophagy
|
Inflammation/Immunology
|
|
Pectolinarigenin (Standard) is the analytical standard of Pectolinarigenin. This product is intended for research and analytical applications. Pectolinarigenin is an orally active dual inhibitor of COX-2/5-LOX with anti-inflammatory, antioxidant, antitumor and neuroprotective activities. Pectolinarigenin exerts neuroprotective and anti-inflammatory effects on astrocyte inflammation via the NFκB and MAPK pathways. Pectolinarigenin inhibits LPS-induced phosphorylation of ERK1/2, N-FκB and p38MAPK, directly inhibits the enzymatic activity or binding of COX-2, 5-LOX and HIF-1α, and reduces the level of XIAP. Pectolinarigenin modifies Keap1 to promote nuclear accumulation of Nrf2, induces ARE-mediated antioxidant enzyme expression, and possesses direct free radical scavenging activity. Pectolinarigenin reduces the release of NO, proinflammatory mediators and leukotrienes, and increases the level of IL-10. Pectolinarigenin induces G2/M cell cycle arrest, apoptosis (Apoptosis) and autophagy (Autophagy) via the PI3K/AKT/mTOR signaling pathway. Pectolinarigenin reduces renal crystal deposition and inhibits melanin synthesis. Pectolinarigenin inhibits inflammation and alleviates allergy in mouse models of inflammation. Pectolinarigenin alleviates renal injury, inflammation and oxidative stress in mice by inhibiting HIF-1α activity. Pectolinarigenin can be used for the research of neurodegenerative diseases, inflammatory/allergic diseases, calcium oxalate nephrocalcinosis, gastric cancer, melasma, post-inflammatory diseases and chloasma.
|
-
- HY-131885
-
|
|
GABA Receptor
|
Neurological Disease
|
|
RuBi-Glutamate hexafluorophosphate sodium is a neuronal activator. RuBi-Glutamate hexafluorophosphate sodium photocleaves to release glutamate upon one- or two-photon excitation, activating glutamate receptors in cortical pyramidal neurons. RuBi-Glutamate hexafluorophosphate sodium reduces peak amplitude of evoked GABAergic inhibitory postsynaptic currents in its caged form. RuBi-Glutamate hexafluorophosphate sodium can be used for the research of Huntington's disease .
|
-
- HY-D2482
-
|
APG-1 AM
|
Fluorescent Dye
|
Neurological Disease
|
|
Asante potassium green-1 AM (APG-1 AM) is a cell-permeable K +-sensitive fluorescent indicator and potassium ion indicator that exhibits minimal interference from Na + and pH at physiologically relevant intracellular levels. Asante potassium green-1 AM enables non-invasive monitoring and quantitative analysis of intracellular potassium ion concentration (ᵢ) . Its excitation/emission maxima are 525/545 nm, respectively.
|
-
- HY-175340
-
|
|
Potassium Channel
TSPO
|
Neurological Disease
|
|
Kv7.2/Kv7.3 activator-3 (GRT-X) is an orally active Kv7.2/Kv7.3 and TSPO activator. Kv7.2/Kv7.3 activator-3 activates Kv7.2/Kv7.3, Kv7.4, and Kv7.5 with EC50 values of 0.37, 2.06, and 0.75 μM, respectively, and binds to TSPO with Ki values of 0.07 μM (rat membrane) and 4.60 μM (human U-118 MG cells). Kv7.2/Kv7.3 activator-3 prevents motor neuron degeneration in mice and humans conditioned by ALS/FTD astrocytes. Kv7.2/Kv7.3 activator-3 stimulates dorsal root ganglion axonal growth through TSPO and Kv7.2/3 activation. Kv7.2/Kv7.3 activator-3 has anti-epileptic effects in epileptic seizure models. Kv7.2/Kv7.3 activator-3 reduces pain hypersensitivity in patients with diabetic neuropathy, promotes neuronal survival and regeneration after cervical neuropathy in rats, and accelerates the recovery of normal function of sensory and motor neurons .
|
-
- HY-P10998
-
|
|
TET Protein
|
Neurological Disease
|
|
Tet1 peptide is a peptide that specifically binds to neurons. Tet1 peptide binds to GT1B ganglioside and trisialoganglioside clostridial toxin receptor on the surface of neuronal cells, and can be used in peptide conjugation and drug delivery research .
|
-
- HY-120717
-
|
|
mGluR
Cytochrome P450
|
Neurological Disease
|
|
VU6001966 is a brain-penetrant and selective mGlu2 receptor inhibitor. VU6001966 blocks mGlu2 receptor activity, counteracts LY379268 (HY-103558)-mediated blood-brain barrier protection and inflammatory cytokine dampening in microglia under inflammatory conditions. VU6001966 enhances antidepressant effects when combined with Scopolamine (HY-N0296). VU6001966 can be used for the research of major depressive disorder .
|
-
- HY-P10502
-
|
|
LDLR
|
Infection
|
|
L57 is a low-density lipoprotein receptor-related protein 1 (LRP1)-binding peptide. L57 exhibits high affinity for LRP1, with an EC50 of 45 nM. L57 possesses blood-brain barrier (BBB) permeability and plasma stability. L57 can serve as a carrier for central nervous system drug delivery .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-101878
-
|
Sulforhodamine 101; SR101
|
Fluorescent Dye
|
|
Texas Red (Sulforhodamine 101) is an amphoteric rhodamine red fluorescent dye (excitation/emission: 586/605 nm). Texas Red is used extensively for investigating neuronal morphology and acts as acell type-selective fluorescent marker of astrocytes bothin vivoand in slice preparations .
|
-
- HY-D2155
-
|
|
Fluorescent Dye
|
|
Texas red-X 4-succinimidyl ester is a derivative of Texas Red (HY-101878), an amphoteric rhodamine red fluorescent dye. Texas Red is widely used to study neuronal morphology and as a cell type-selective fluorescent marker for astrocytes, both in vivo and in slice preparations.
|
-
- HY-D2482
-
|
APG-1 AM
|
Fluorescent Dye
|
|
Asante potassium green-1 AM (APG-1 AM) is a cell-permeable K +-sensitive fluorescent indicator and potassium ion indicator that exhibits minimal interference from Na + and pH at physiologically relevant intracellular levels. Asante potassium green-1 AM enables non-invasive monitoring and quantitative analysis of intracellular potassium ion concentration (ᵢ) . Its excitation/emission maxima are 525/545 nm, respectively.
|
-
- HY-DY1056
-
|
|
Fluorescent Dye
|
Texas Red (Sulforhodamine 101) (solution) is an amphoteric rhodamine red fluorescent dye (excitation/emission: 586/605 nm). Texas Red is used extensively for investigating neuronal morphology and acts as acell type-selective fluorescent marker of astrocytes bothin vivoand in slice preparations .
Solvent and concentration: DMSO: 10 mM
The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.
|
-
- HY-101878R
-
|
Sulforhodamine 101 (Standard); SR101 (Standard)
|
Fluorescent Dye
|
|
Texas Red (Standard) is the analytical standard of Texas Red (HY-101878). This product is intended for research and analytical applications. Texas Red (Sulforhodamine 101) is an amphoteric rhodamine red fluorescent dye (excitation/emission: 586/605 nm). Texas Red is used extensively for investigating neuronal morphology and acts as acell type-selective fluorescent marker of astrocytes bothin vivoand in slice preparations .
|
-
- HY-D3225
-
|
|
Fluorescent Dye
|
|
MD-B is a •OH Fluorescent probe with blood-brain barrier permeability. MD-B undergoes single-electron oxidation by hydroxyl radicals (•OH), which triggers fluorescence enhancement and enables in-situ imaging of •OH. MD-B allows imaging analysis of hydroxyl radicals (•OH) in the mouse brain, revealing a positive correlation between elevated •OH levels and the severity of depressive phenotypes. MD-B can be used in depression-related research .
|
| Cat. No. |
Product Name |
Type |
-
- HY-NP0204
-
|
|
Biochemical Assay Reagents
|
|
Mouse Serum Albumin is most abundant protein in plasma, which leaks into the brain parenchyma when the blood-brain barrier (BBB) is impaired. Mouse Serum Albumin induces astrocytes to A1 phenotype to remarkably increase levels of Elovl1. Mouse Serum Albumin promotes VLSFAs secretion and causes neuronal lippoapoptosis through endoplasmic reticulum stress response pathway. MSA-activated microglia triggeres remarkable tau phosphorylation at multiple sites (Ser202/Thr205) through NLRP3 inflammasome pathway. Mouse Serum Albumin decreases the spatial learning and memory abilities in mice. Mouse Serum Albumin can be used for the study of neurodegenerative diseases like Alzheimer’s disease (AD) and frontotemporal dementia (FTD) .
|
-
- HY-P3394
-
|
CTB, from vibrio cholerae
|
Biochemical Assay Reagents
|
|
Cholera toxin B subunit, from vibrio cholerae (CTB, from vibrio cholerae) is non-toxic to cells and possesses no intrinsic adenylate cyclase activity. Cholera toxin B subunit, from vibrio cholerae attaches to cells by binding to ganglioside GM1.8 CTB has been shown to be a good label for microglial cells (due to the enrichment of ganglioside GM1 on their cell surface), but not for oligodendrocytes or astrocytes. Cholera toxin B subunit, from vibrio cholerae has been reported to be an excellent tracer for the study of axonal transport using immunohistochemical methods. Cholera toxin B subunit, from vibrio cholerae has been widely used as a marker of membrane lipid rafts .
|
-
- HY-W782399
-
|
Sodium boranocarbonate
|
Biochemical Assay Reagents
|
|
CORM-A1 (Sodium boranocarbonate) is a water-soluble carbon monoxide (CO) releasing molecule that facilitates the investigation of CO's impact on cellular systems. As CO is generated from heme degradation by the enzyme heme oxygenase, it serves as a crucial gaseous signaling mediator in mammalian cells. CORM-A1 not only exhibits anti-oxidant and anti-inflammatory properties but also regulates CO release in a manner dependent on pH and temperature, promoting mild vasorelaxation and hypotension. Furthermore, CORM-A1 has been shown to provide cytoprotection in primary cultures of astrocytes under oxidative stress while also enhancing autophagy due to its boron-containing composition.
|
-
- HY-172705
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG2000-RVG29 is a PEG conjugate composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB), crosses the BBB, and mediates receptor-dependent transcytosis. DSPE-PEG2000-RVG29 can be used for brain-targeted drug delivery, surface modification of nanocarriers, as well as gene and nucleic acid delivery. DSPE-PEG2000-RVG29 is applicable to research related to hypoxic-ischemic brain injury, Parkinson's disease, and other conditions .
|
-
- HY-W040074
-
|
Diglycine hydrochloride hydrate; Gly-Gly (HCl H2O)
|
Biochemical Assay Reagents
|
|
Glycylglycine hydrochloride hydrate is a non-selective Glycylglycine hydrochloride hydrate dipeptidase substrate and iNOS inhibitor. Glycylglycine hydrochloride hydrate can cross the cell membrane by passive diffusion and is hydrolyzed to glycine in the cell, participating in energy metabolism and antioxidant processes. Glycylglycine hydrochloride hydrate promotes spermatogonial stem cells (SSCs) proliferation, inhibits astrocyte overactivation and reduces nitric oxide (NO) release, while upregulating the expression of neurotrophic factors (such as PDGFA, FGF2, CNTF) to support nerve myelin repair. Glycylglycine hydrochloride hydrate can be used to study male reproductive biology (such as SSCs proliferation regulation) and neurodegenerative diseases (such as neuroprotective mechanisms in multiple sclerosis) .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1410
-
GsMTx4
Maximum Cited Publications
112 Publications Verification
|
TRP Channel
Piezo Channel
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
GsMTx4 is a spider venom peptide that selectively inhibits cationic-permeable mechanosensitive channels (MSCs) belonging to the Piezo and TRP channel families. GsMTx4 also blocks cation-selective stretch-activated channels (SACs) , attenuates lysophosphatidylcholine (LPC)-induced astrocyte toxicity and microglial reactivity. GsMTx4 is an important pharmacological tool for identifying the role of these excitatory MSCs in normal physiology and pathology .
|
-
- HY-P1410A
-
GsMTx4 TFA
Maximum Cited Publications
112 Publications Verification
|
TRP Channel
Piezo Channel
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
GsMTx4 TFA is a spider venom peptide that selectively inhibits cationic-permeable mechanosensitive channels (MSCs) belonging to the Piezo and TRP channel families. GsMTx4 TFA also blocks cation-selective stretch-activated channels (SACs) , attenuates lysophosphatidylcholine (LPC)-induced astrocyte toxicity and microglial reactivity. GsMTx4 TFA is an important pharmacological tool for identifying the role of these excitatory MSCs in normal physiology and pathology .
|
-
- HY-D0889
-
|
Gly-Gly; H-Gly-Gly-OH
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Glycylglycine is a non-selective glycylglycine dipeptidase substrate and iNOS inhibitor. Glycylglycine can cross the cell membrane by passive diffusion and is hydrolyzed to glycine in the cell, participating in energy metabolism and antioxidant processes. Glycylglycine promotes spermatogonial stem cells (SSCs) proliferation, inhibits astrocyte overactivation and reduces nitric oxide (NO) release, while upregulating the expression of neurotrophic factors (such as PDGFA, FGF2, CNTF) to support nerve myelin repair. Glycylglycine can be used to study male reproductive biology (such as SSCs proliferation regulation) and neurodegenerative diseases (such as neuroprotective mechanisms in multiple sclerosis) .
|
-
- HY-P1146
-
Semax
1 Publications Verification
|
Amyloid-β
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Semax is a BBB-penetrable adrenocorticotropic hormone-like peptide and can form stable complexes with Cu 2+. Semax is a synthetic peptide analog of Adrenocorticotropic hormone (ACTH) (4-10). Semax has immunomodulatory, nootropic and neuroprotective activities. Semax can be used in the research of central nervous system diseases such as Alzheimer's disease and cerebral ischemia .
|
-
- HY-P10502
-
|
|
LDLR
|
Infection
|
|
L57 is a low-density lipoprotein receptor-related protein 1 (LRP1)-binding peptide. L57 exhibits high affinity for LRP1, with an EC50 of 45 nM. L57 possesses blood-brain barrier (BBB) permeability and plasma stability. L57 can serve as a carrier for central nervous system drug delivery .
|
-
- HY-P1146A
-
|
|
Amyloid-β
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Semax acetate is a BBB-penetrable adrenocorticotropic hormone-like peptide and can form stable complexes with Cu 2+. Semax acetate is a synthetic peptide analog of Adrenocorticotropic hormone (ACTH) (4-10). Semax acetate has immunomodulatory, nootropic and neuroprotective activities. Semax acetate can be used in the research of central nervous system diseases such as Alzheimer's disease and cerebral ischemia .
|
-
- HY-P10019
-
|
NLY01
|
GCGR
|
Neurological Disease
Inflammation/Immunology
|
|
Pegsebrenatide (NLY01) is a blood-brain barrier-penetrant GLP-1R agonist. Pegsebrenatide alleviates retinal inflammation and neuronal death secondary to ocular hypertension . Pegsebrenatide significantly delays onset and reduces disease severity in experimental autoimmune encephalomyelitis . Pegsebrenatide inhibits the formation of A1 reactive astrocytes in nerve cells and reduces the loss of retinal ganglion cells and dopaminergic neurons. Pegsebrenatide exerts neuroprotective effects in a mouse model of Parkinson's disease by directly preventing microglia-mediated conversion of astrocytes to the A1 neurotoxic phenotype. Pegsebrenatide can be used for research on glaucoma, Parkinson's disease, and multiple sclerosis .
|
-
- HY-P10557
-
|
|
Biochemical Assay Reagents
|
Neurological Disease
|
|
DAG peptide is a cyclic peptide. DAG peptide selectively recognizes a subset of astrocytes that are activated in Alzheimer's disease (AD) starting at an early stage of the disease. DAG peptide can be used as a tool to enhance the delivery of therapeutics and imaging agents to sites of vascular changes and astrogliosis in diseases associated with neuroinflammation .
|
-
- HY-D0889R
-
|
Gly-Gly (Standard); H-Gly-Gly-OH (Standard)
|
Reference Standards
Endogenous Metabolite
|
Metabolic Disease
|
|
Glycylglycine (Standard) is the analytical standard of Glycylglycine (HY-D0889). This product is intended for research and analytical applications. Glycylglycine is a non-selective glycylglycine dipeptidase substrate and iNOS inhibitor. Glycylglycine can cross the cell membrane by passive diffusion and is hydrolyzed to glycine in the cell, participating in energy metabolism and antioxidant processes. Glycylglycine promotes spermatogonial stem cells (SSCs) proliferation, inhibits astrocyte overactivation and reduces nitric oxide (NO) release, while upregulating the expression of neurotrophic factors (such as PDGFA, FGF2, CNTF) to support nerve myelin repair. Glycylglycine can be used to study male reproductive biology (such as SSCs proliferation regulation) and neurodegenerative diseases (such as neuroprotective mechanisms in multiple sclerosis) .
|
-
- HY-P10998
-
|
|
TET Protein
|
Neurological Disease
|
|
Tet1 peptide is a peptide that specifically binds to neurons. Tet1 peptide binds to GT1B ganglioside and trisialoganglioside clostridial toxin receptor on the surface of neuronal cells, and can be used in peptide conjugation and drug delivery research .
|
-
- HY-100838
-
|
L-CCG III
|
EAAT
|
Neurological Disease
|
|
cis-α-(Carboxycyclopropyl)glycine (L-CCG III) is a potent, competitive glutamate uptake inhibitor. cis-α-(Carboxycyclopropyl)glycine is a substrate of glutamate transporters (GluT) (EC50: 13 μM, 2 μM for EAAT 1 and EAAT 2, respectively). cis-α-(Carboxycyclopropyl)glycine inhibits a Na +-dependent high-affinity L-glutamate uptake in glial plasmalemmal vesicles (GPV) and synaptosomes .
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P990110
-
|
Mab158
|
Amyloid-β
|
Neurological Disease
|
|
Lecanemab (Mouse IGG2a) (Mab158) is a monoclonal antibody that targets soluble β-amyloid and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IGG2a sequence. Lecanemab (Mouse IGG2a) almost abolishes Aβ accumulation in astrocytes and rescues neurons from Aβ-induced cell death. Lecanemab (Mouse IGG2a) holds promise for research in the field of Alzheimer's disease .
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-100803
-
-
-
- HY-B1614
-
-
-
- HY-N0474
-
-
-
- HY-D0889
-
-
-
- HY-N0493
-
|
|
Structural Classification
Flavonoids
Classification of Application Fields
Flavones
Campylotropis hirtella (Franch.) Schindl.
Phenols
Polyphenols
Plants
Compositae
Inflammation/Immunology
Disease Research Fields
Source Classification
|
COX
Lipoxygenase
NF-κB
p38 MAPK
ERK
HIF/HIF Prolyl-Hydroxylase
Keap1-Nrf2
PI3K
Apoptosis
Autophagy
|
|
Pectolinarigenin is an orally active dual inhibitor of COX-2/5-LOX with anti-inflammatory, antioxidant, antitumor and neuroprotective activities. Pectolinarigenin exerts neuroprotective and anti-inflammatory effects on astrocyte inflammation via the NFκB and MAPK pathways. Pectolinarigenin inhibits LPS-induced phosphorylation of ERK1/2, N-FκB and p38MAPK, directly inhibits the enzymatic activity or binding of COX-2, 5-LOX and HIF-1α, and reduces the level of XIAP. Pectolinarigenin modifies Keap1 to promote nuclear accumulation of Nrf2, induces ARE-mediated antioxidant enzyme expression, and possesses direct free radical scavenging activity. Pectolinarigenin reduces the release of NO, proinflammatory mediators and leukotrienes, and increases the level of IL-10. Pectolinarigenin induces G2/M cell cycle arrest, apoptosis (Apoptosis) and autophagy (Autophagy) via the PI3K/AKT/mTOR signaling pathway. Pectolinarigenin reduces renal crystal deposition and inhibits melanin synthesis. Pectolinarigenin inhibits inflammation and alleviates allergy in mouse models of inflammation. Pectolinarigenin alleviates renal injury, inflammation and oxidative stress in mice by inhibiting HIF-1α activity. Pectolinarigenin can be used for the research of neurodegenerative diseases, inflammatory/allergic diseases, calcium oxalate nephrocalcinosis, gastric cancer, melasma, post-inflammatory diseases and chloasma .
|
-
-
- HY-136341
-
-
-
- HY-N0061
-
-
-
- HY-121362
-
|
|
Structural Classification
other families
Classification of Application Fields
Ketones, Aldehydes, Acids
Plants
Inflammation/Immunology
Disease Research Fields
Source Classification
|
Bacterial
Endogenous Metabolite
TrxR
|
|
Evernic Acid is an orally active thioredoxin reductase 1 (TrxR1) inhibitor and antiproliferative agent. Evernic Acid inhibits the proliferation and migration of human breast cancer cells. Evernic Acid blocks the NF-κB pathway by inhibiting p65 nuclear translocation and IκBα phosphorylation, thereby suppressing downstream inflammatory mediators. Evernic Acid acts as an antioxidant, anti-inflammatory agent and neuroprotective agent, protects neurons from cell death, mitochondrial dysfunction and oxidative stress damage, reduces astrocyte activation, and ameliorates dopaminergic neuron loss and neuroinflammation. Evernic Acid inhibits enoyl reductases FabI and FabZ of Plasmodium falciparum. Evernic Acid downregulates the expression of lasB and rhlA genes in Pseudomonas aeruginosa, inhibits quorum sensing and biofilm formation, and exerts antibacterial activity against Gram-positive bacteria, Gram-negative bacteria and fungi. Evernic Acid is applicable to research related to breast cancer, Parkinson's disease, bacterial infections and fungal infections .
|
-
-
- HY-N0167
-
-
-
- HY-113468A
-
|
3-Methoxy-L-tyrosine; 3-O-Methyl-L-DOPA
|
Monophenols
Ketones, Aldehydes, Acids
Phenols
Endogenous metabolite
Source Classification
|
Drug Derivative
Interleukin Related
|
|
3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease .
|
-
-
- HY-N7526
-
-
-
- HY-N0092R
-
-
-
- HY-N0474R
-
-
-
- HY-D0889R
-
|
Gly-Gly (Standard); H-Gly-Gly-OH (Standard)
|
Structural Classification
Ketones, Aldehydes, Acids
Endogenous metabolite
Source Classification
|
Reference Standards
Endogenous Metabolite
|
|
Glycylglycine (Standard) is the analytical standard of Glycylglycine (HY-D0889). This product is intended for research and analytical applications. Glycylglycine is a non-selective glycylglycine dipeptidase substrate and iNOS inhibitor. Glycylglycine can cross the cell membrane by passive diffusion and is hydrolyzed to glycine in the cell, participating in energy metabolism and antioxidant processes. Glycylglycine promotes spermatogonial stem cells (SSCs) proliferation, inhibits astrocyte overactivation and reduces nitric oxide (NO) release, while upregulating the expression of neurotrophic factors (such as PDGFA, FGF2, CNTF) to support nerve myelin repair. Glycylglycine can be used to study male reproductive biology (such as SSCs proliferation regulation) and neurodegenerative diseases (such as neuroprotective mechanisms in multiple sclerosis) .
|
-
-
- HY-B1614R
-
-
-
- HY-100803R
-
-
-
- HY-N8713
-
-
-
- HY-136341R
-
-
-
- HY-N0493R
-
|
|
Structural Classification
Flavonoids
Flavones
Campylotropis hirtella (Franch.) Schindl.
Phenols
Polyphenols
Plants
Compositae
Source Classification
|
Reference Standards
COX
Lipoxygenase
NF-κB
p38 MAPK
ERK
HIF/HIF Prolyl-Hydroxylase
Keap1-Nrf2
PI3K
Apoptosis
Autophagy
|
|
Pectolinarigenin (Standard) is the analytical standard of Pectolinarigenin. This product is intended for research and analytical applications. Pectolinarigenin is an orally active dual inhibitor of COX-2/5-LOX with anti-inflammatory, antioxidant, antitumor and neuroprotective activities. Pectolinarigenin exerts neuroprotective and anti-inflammatory effects on astrocyte inflammation via the NFκB and MAPK pathways. Pectolinarigenin inhibits LPS-induced phosphorylation of ERK1/2, N-FκB and p38MAPK, directly inhibits the enzymatic activity or binding of COX-2, 5-LOX and HIF-1α, and reduces the level of XIAP. Pectolinarigenin modifies Keap1 to promote nuclear accumulation of Nrf2, induces ARE-mediated antioxidant enzyme expression, and possesses direct free radical scavenging activity. Pectolinarigenin reduces the release of NO, proinflammatory mediators and leukotrienes, and increases the level of IL-10. Pectolinarigenin induces G2/M cell cycle arrest, apoptosis (Apoptosis) and autophagy (Autophagy) via the PI3K/AKT/mTOR signaling pathway. Pectolinarigenin reduces renal crystal deposition and inhibits melanin synthesis. Pectolinarigenin inhibits inflammation and alleviates allergy in mouse models of inflammation. Pectolinarigenin alleviates renal injury, inflammation and oxidative stress in mice by inhibiting HIF-1α activity. Pectolinarigenin can be used for the research of neurodegenerative diseases, inflammatory/allergic diseases, calcium oxalate nephrocalcinosis, gastric cancer, melasma, post-inflammatory diseases and chloasma.
|
-
-
- HY-N19845
-
-
| Cat. No. |
Compare |
Product Name |
Species |
Source |
Image |
Compare Products
|
| Products |
|
| Cat. No. |
|
| Species |
|
| Source |
|
| Tag |
|
| Accession |
|
| Gene ID |
|
| Molecular Weight |
|
| Purity |
|
| Endotoxin Level |
|
| Biological Activity |
|
| Appearance |
|
| Formulation |
|
| Storage & Stability |
|
| Shipping |
|
| Free Sample |
Yes
No
|
| Size |
* This product has been "discontinued".
Optimized version of product available:
|
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-113468AS
-
|
|
|
3-O-Methyldopa-d3 (3-Methoxy-L-tyrosine-d3) is deuterium labeled 3-O-Methyldopa (HY-113468A). 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease .
|
-
-
- HY-115708S
-
|
|
|
C22 Phytoceramide-d3 (t18:0/22:0) is a deuterated labeled C22 Phytoceramide (t18:0/22:0) . C22 Phytoceramide is a sphingolipid that has been found in Moro blood orange (C. sinensis) peels. It has also been found in primary human astrocytes.
|
-
-
- HY-B0712S1
-
|
|
|
Ceftriaxone-13C2,d3 triethylammonium salt is 13C and deuterated labeled Ceftriaxone (HY-B0712). Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 mM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis .
|
-
-
- HY-113468AS1
-
|
|
|
3-O-Methyldopa-d3 (hydrate) is the deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa (3-Methoxy-L-tyrosine) hydrate is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa hydrate inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa hydrate has certain antidepressant and neuroprotective activities. 3-O-Methyldopa hydrate can be used in the research of nervous system diseases such as depression and Parkinson's disease .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-142035
-
|
|
|
Alkynes
|
|
N-Propargylglycine is a brain-penetrant and orally active PRODH inhibitor. N-Propargylglycine covalently modifies enzyme-bound FAD and active site lysine, causing enzyme structural distortion, protein decay, and irreversible inhibition of proline and 4-hydroxyproline catabolism. N-Propargylglycine induces UPRmt, upregulates mitochondrial chaperones and YME1L1, enhances mitochondrial proteostasis, blocks astrocytic L-proline consumption, and abolishes L-proline’s ATP-maintaining and viability-protective effects. N-Propargylglycine stimulates neural processes, increases brain proline, hydroxyproline, and sarcosine levels, partially normalizes Huntington’s disease whole brain transcriptomes. N-Propargylglycine reduces hyperoxaluria, prevents calcium oxalate stone formation, reduces kidney tubular damage, and restores weight and survival in Grhpr knockout mice. N-Propargylglycine can be used for the research of breast cancer, neurodegenerative disorders, Huntington’s disease, and primary hyperoxaluria type 2 .
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-172705
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-RVG29 is a PEG conjugate composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB), crosses the BBB, and mediates receptor-dependent transcytosis. DSPE-PEG2000-RVG29 can be used for brain-targeted drug delivery, surface modification of nanocarriers, as well as gene and nucleic acid delivery. DSPE-PEG2000-RVG29 is applicable to research related to hypoxic-ischemic brain injury, Parkinson's disease, and other conditions .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
